![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/05/16/2883333/0/en/BeyondSpring-R-D-Day-Highlights-New-Plinabulin-Development-Strategy-for-Cancer-and-Updates-for-SEED-Therapeutics.html
https://www.globenewswire.com/news-release/2024/05/03/2875017/0/en/BeyondSpring-To-Host-Virtual-R-D-Day-to-Discuss-New-Plinabulin-Development-Strategy-for-Cancer-and-Updates-for-SEED-Therapeutics.html
https://www.globenewswire.com/news-release/2024/04/29/2871704/0/en/BeyondSpring-Provides-Business-Update-and-Reports-Year-End-2023-Financial-Results.html
https://www.globenewswire.com/news-release/2024/03/25/2851479/0/en/BeyondSpring-Announces-First-Patient-Dosed-with-Pembrolizumab-Plinabulin-Plus-Etoposide-Platinum-in-a-Phase-2-Investigator-initiated-Study-of-First-Line-Extensive-Stage-Small-Cell-.html
https://www.globenewswire.com//news-release/2023/11/07/2774892/0/en/BeyondSpring-Presents-Poster-Highlighting-Preclinical-and-Clinical-POC-Immunomodulating-Activity-of-Plinabulin-Inducing-Dendritic-Cell-Maturation-and-Re-sensitization-in-Immunother.html
https://www.globenewswire.com/news-release/2022/12/13/2572669/0/en/BeyondSpring-Presents-Positive-Data-with-Plinabulin-for-the-Prevention-of-Docetaxel-Induced-Neutropenia-in-Patients-with-Non-Small-Cell-Lung-Cancer-and-Breast-Cancer-at-Three-Medic.html
https://www.globenewswire.com/news-release/2022/08/29/2505800/0/en/BeyondSpring-Presents-New-Data-for-the-Use-of-Plinabulin-and-Pegfilgrastim-to-Decrease-Neutropenia-Burden-in-Peri-Transplant-Multiple-Myeloma-Patients-at-the-19th-International-Mye.html
https://www.globenewswire.com/news-release/2021/12/10/2350028/0/en/BeyondSpring-Pharmaceuticals-Announces-Analysis-of-New-Data-on-the-Plinabulin-Pegfilgrastim-Combination-in-Breast-Cancer-at-the-2021-San-Antonio-Breast-Cancer-Symposium.html
https://www.fiercebiotech.com/biotech/beyondspring-lurches-down-as-fda-rejects-plinabulin-raising-questions-about-lung-cancer
https://www.globenewswire.com/news-release/2021/10/20/2317228/0/en/BeyondSpring-Pharmaceuticals-Announces-New-Patient-Derived-Cancer-Model-Data-for-Plinabulin-Monotherpy-at-the-AACR-NCI-EORTC-Virtual-International-Conference-to-Further-Support-the.html
https://www.evaluate.com/vantage/articles/news/snippets/esmo-2021-beyondspring-experiences-winter-discontent
https://www.statnews.com/2021/09/20/beyondspring-drug-lung-cancer-study-results-debate/
https://endpts.com/playing-a-surprisingly-hot-hand-beyondspring-nails-a-200m-china-deal-in-wake-of-a-pivotal-success/
https://www.globenewswire.com/news-release/2021/06/17/2249305/0/en/BeyondSpring-to-Host-R-D-Day-to-Discuss-Novel-Immune-Agent-Plinabulin-s-Development-Program-in-Anti-cancer-Indications.html
https://www.globenewswire.com/news-release/2021/06/10/2245057/0/en/BeyondSpring-Announces-Final-Positive-Data-from-the-PROTECTIVE-1-Phase-3-CIN-Program-of-Plinabulin-as-a-Single-Agent-Compared-to-Pegfilgrastim-at-the-American-Society-of-Clinical-O.html
https://www.globenewswire.com/news-release/2021/06/08/2243453/0/en/BeyondSpring-Announces-a-Late-Breaking-Poster-Presentation-of-PROTECTIVE-2-Phase-3-Data-Showing-Plinabulin-in-Combination-with-Pegfilgrastim-Reverses-the-Immune-Suppressive-Effects.html
http://www.globenewswire.com/news-release/2021/04/01/2202986/0/en/BeyondSpring-Announces-Submission-of-New-Drug-Application-to-U-S-FDA-and-China-NMPA-for-Plinabulin-and-G-CSF-Combination-for-the-Prevention-of-Chemotherapy-Induced-Neutropenia-CIN.html
https://www.globenewswire.com/fr/news-release/2020/09/24/2098615/0/en/New-Data-Highlights-BeyondSpring-s-Plinabulin-as-a-Highly-Effective-Agent-for-Preventing-Chemotherapy-Induced-Neutropenia-with-Potential-to-Reduce-Clinical-Resources-for-COVID-19.html
https://www.globenewswire.com/news-release/2020/06/03/2042875/0/en/BeyondSpring-Announces-Data-Safety-Monitoring-Board-Recommendation-for-Plinabulin-to-Continue-NSCLC-Phase-3-Dublin-3-Study-Without-Modification.html